Gosebruch named CEO of Neumora
Plus: Petti becomes CEO at Leucid Bio, and updates from Acelyrin, Larimar, Pharming and more
Neuroscience company Neumora Therapeutics Inc. named Henry Gosebruch as president, CEO and board member. Gosebruch succeeds co-founder, chairman and CEO Paul Berns, who will transition to executive chairman. Gosebruch was EVP and chief strategy officer at AbbVie Inc. (NYSE:ABBV). Neumora also announced Tuesday that it had completed an end of Phase II meeting with FDA and planned to start the first of three Phase III KOSTAL trials of lead therapy navacaprant (NMRA-140) in 3Q23. The KOR antagonist is in development to treat major depressive disorder.
Filippo Petti has taken on the CEO role at Leucid Bio Ltd., a CAR T therapy company. Petti was CEO and CFO at Celyad Oncology S.A. (Euronext:CYAD; Pink:CYADY), before which he was a healthcare investment banker at Wells Fargo and William Blair...